Navigation Links
New robotic head and neck cancer surgery preserves speech, without scarring
Date:9/7/2010

DETROIT An incisionless robotic surgical procedure is offering patients a new option to remove certain head and neck cancer tumors without visible scarring, while preserving speech and the ability to eat.

Henry Ford Hospital in Detroit is among the first in the country to perform TransOral Robotic Surgery (TORS) using the da Vinci Surgical System. Unlike traditional surgical approaches to head and neck cancer, TORS patients are able to return to their normal lives only a few days after surgery without significant pain and disfigurement.

"TORS offers shorter post-operative recovery than standard open surgical approaches, giving patients the opportunity to quickly and successfully return to their normal lives," says Tamer A. Ghanem, M.D., Ph.D., director of Head and Neck Oncology and Reconstructive Surgery Division in the Department of OtolaryngologyHead & Neck Surgery at Henry Ford Hospital.

"TORS allows surgeons to completely remove tumors of the head and neck while preserving speech, swallowing, and other key quality of life issues such as eating. There also is no visible scaring or disfigurement."

Led by Dr. Ghanem, Henry Ford Hospital has performed more than a dozen TORS procedures since it was approved in January by the U.S. Food and Drug Administration to remove malignant and benign tumors of the mouth, tongue, tonsils, and parts of the throat.

Prior to TORS, patients would traditionally begin treatment with radiation therapy, or a combination of chemotherapy and radiation therapy, depending on the stage of their cancer. Side effects of radiation dry mouth, loss of taste and difficulty swallowing can potentially be avoided with TORS

Traditional surgery has side effects as well. It requires a long incision be made across the lip and jaw to access the tumor. This approach can results in significant swelling, longer post-operative recovery, damage to surrounding structures, and speech and swallowing problems.

With TORS, surgeons can access tumors through the mouth using the slender operating arms of the da Vinci, thus not requiring an open skin incision.

"Surgeons operate with greater precision and control using the TORS approach," says Dr. Ghanem, "minimizing the pain, and reducing the risk of possible nerve and tissue damage associated with large incisions."

Some of TORS's other benefits include:

  • Significantly less blood loss
  • No visible scarring
  • Possibility of avoiding a tracheotomy
  • Minimization or elimination of need for chemoradiation therapy
  • Fewer complications and shorter hospital stay
  • Faster recovery, return to normal speech and swallowing
  • Equivalent cancer control to radiation therapy

Patients with early stage tonsil and base of tongue cancers may not need to receive radiation therapy following TORS, depending on the final tumor margins and pathological characteristics of the tumor.

In addition to TORS, Dr. Ghanem specializes in complex head and neck oncology cases, offering both cancer resection as well as reconstructive surgery using microvascular techniques (taking tissue from one part of the body and transplanting it to the head and neck areas to improve function and esthetics). In addition, he performs thyroid, parathyroid, and salivary gland surgery, reconstruction after Mohs procedures and robotic-assisted thyroidectomy, in which the incision is made in the arm pit instead of the neck to conceal it.


'/>"/>

Contact: Krista Hopson
khopson1@hfhs.org
313-874-7207
Henry Ford Health System
Source:Eurekalert  

Related medicine news :

1. Pre-emptive pain regimen decreased opioid usage in patients undergoing robotic prostatectomy
2. Robotic-assisted vasectomy reversal offers greater chance of fatherhood
3. Introducing RoSS, a flight simulator for robotic surgery
4. LA BioMed research finds hallucinogen can safely ease anxiety in advanced-stage cancer patients
5. Hallucinogen appears safe, may improve mood among patients with advanced-stage cancer and anxiety
6. Long-Term Use of Bone Drugs May Be Linked to Esophageal Cancer
7. Basal-like breast cancer does not originate from basal stem cells
8. Study finds that cancer-causing gene crucial in stem cell development
9. Microsoft Excel-based algorithm predicts cancer prognosis
10. Diabetes Drug Metformin Linked to Lower Lung Cancer Rate in Mice
11. Targeted strategies needed to find, prevent and treat breast cancer among Mexican-origin women
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
New robotic head and neck cancer surgery preserves speech, without scarring
(Date:8/16/2017)... ... August 16, 2017 , ... The next Patient Care Academy ... , Students who successfully complete the seven-week long Patient Care Academy are eligible ... The average starting salary for a CNA in Kalamazoo is $24,428.* , As a ...
(Date:8/16/2017)... , ... August 16, 2017 , ... Greenfield Advisors is ... in the U.S. for the second year in a row. The Inc. 5000 list ... three years. , “To be on the list once is a great accomplishment, but ...
(Date:8/16/2017)... ... August 16, 2017 , ... Any Lab Test Now® is thrilled ... on the newly released, 36th annual Inc. 5000 , the most prestigious compilation ... most successful companies within the American economy’s most dynamic segment — its independent small ...
(Date:8/16/2017)... ... 2017 , ... In a recent survey, eighty-two percent of women reported having ... cellulite can't always be eliminated by diet and exercise alone, and now for the ... nationwide. Dr. Kenneth Rothaus has recently added Cellulaze™ to his practice in ...
(Date:8/16/2017)... , ... August 16, 2017 , ... Maury Regional Health ... and blood draws. By broadly deploying AccuVein devices, Maury Regional Medical Center is making ... the guesswork out of a needle stick and more importantly, helps our staff members ...
Breaking Medicine News(10 mins):
(Date:8/1/2017)... , Aug. 1, 2017   CerSci Therapeutics , ... Dallas, Texas , has received notice from the ... Institutes of Health (NIH) that it has been awarded ... totaling over $650,000 in 2017 with an additional $1,000,000 ... Investigational New Drug application of their lead non-opioid drug ...
(Date:7/28/2017)... , July 28, 2017 EnvoyHealth, a Diplomat ... pilot a program for CleverCap LITE, a technology designed ... strives to deliver innovative health technology solutions and services ... CleverCap LITE offers medication ... high-tech bottle cover: ...
(Date:7/26/2017)... Fla. , July 26, 2017 Sancilio ... enrollment of our clinical trial evaluating Altemia TM , ... Anemia (SCA) and Sickle Cell Disease (SCD). The SCOT ... evaluate the efficacy and safety of Altemia TM ... is conducted under US IND 125274. ...
Breaking Medicine Technology: